ArticleJournal of intensive care2017
Argatroban for an alternative anticoagulant in HIT during ECMO.
Article in Journal of intensive care, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Alternative Anticoagulation for Patients with Heparin-Induced Thrombocytopenia on ECMO: A Narrative Review.Biomedicines · 2025Review
- A safety comparison of heparin and argatroban anticoagulation in veno-venous extracorporeal membrane oxygenation with a focus on bleeding.Transfusion medicine (Oxford, England) · 2025Observational
- The role of extracorporeal membrane oxygenation in the management of heparin-induced thrombocytopenia with total occlusion of a native coronary artery: a case report.Anaesthesiology intensive therapy · 2024Article
- Heparin-Induced Thrombocytopenia in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation.Journal of clinical medicine · 2023Article
- Prevalence and outcomes of patients developing heparin-induced thrombocytopenia during extracorporeal membrane oxygenation.PloS one · 2022Article
- New challenges in cardiac intensive care units.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Article
- Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021Article
- Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices.European heart journal. Acute cardiovascular care · 2021Article
- Anticoagulation in ECMO patients: an overview.Indian journal of thoracic and cardiovascular surgery · 2021Review
- Extracorporeal Life Support for Cardiac Arrest and Cardiogenic Shock.US cardiology · 2021Review
- Suspected heparin-induced thrombocytopenia in a COVID-19 patient on extracorporeal membrane oxygenation support: a case report.Thrombosis journal · 2020Article
- Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support.Intensive care medicine · 2020Article
- Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation.World journal of critical care medicine · 2019Review
- Heparin-induced thrombocytopenia during extracorporeal life support: incidence, management and outcomes.Annals of cardiothoracic surgery · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracorporeal membrane oxygenation (ECMO) have become more frequently used in daily ICU practice, heparin-induced thrombocytopenia (HIT) is a rare but life-threatening complication while on extracorporeal membrane oxygenation (ECMO). HIT confirmation directly impacts on anticoagulant strategy requiring no delay unfractionated heparin discontinuation to be replaced by alternative systemic anticoagulant treatment. CASE PRESENTATION: We report two clinical cases of HIT occurring during ECMO in various settings with subsequent recovery with argatroban and provide literature review to help physicians treat HIT during ECMO in clinical daily practice.
conclusionsHIT during ECMO is uncommon, and despite the absence of recommendation, argatroban seems to be an appropriate and safe therapeutic option. Finally, there are not enough arguments favouring routine circuit change in the event of HIT during ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.